Despite the shift in the trading schedule, the subscription period for the rights issue remains unchanged. Investors have until September 29, 2026, to participate in the offering. Following the commencement of trading on September 16, subscription rights will be available for exchange through September 24, while paid-up subscribed shares, known as BTA, will remain active until October 16, 2026.

The Stockholm-based medical technology company, which specializes in AI-driven dermatological diagnostics, expects to announce the final outcome of the rights issue on October 1, 2026. The firm maintains that all other operational aspects of the capital raise remain consistent with previously disclosed information.